Cargando…
Rapamycin Pharmacokinetic and Pharmacodynamic Relationships in Osteosarcoma: A Comparative Oncology Study in Dogs
BACKGROUND: Signaling through the mTOR pathway contributes to growth, progression and chemoresistance of several cancers. Accordingly, inhibitors have been developed as potentially valuable therapeutics. Their optimal development requires consideration of dose, regimen, biomarkers and a rationale fo...
Autores principales: | Paoloni, Melissa C., Mazcko, Christina, Fox, Elizabeth, Fan, Timothy, Lana, Susan, Kisseberth, William, Vail, David M., Nuckolls, Kaylee, Osborne, Tanasa, Yalkowsy, Samuel, Gustafson, Daniel, Yu, Yunkai, Cao, Liang, Khanna, Chand |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2882366/ https://www.ncbi.nlm.nih.gov/pubmed/20543980 http://dx.doi.org/10.1371/journal.pone.0011013 |
Ejemplares similares
-
The Comparative Oncology Trials Consortium: Using Spontaneously Occurring Cancers in Dogs to Inform the Cancer Drug Development Pathway
por: Gordon, Ira, et al.
Publicado: (2009) -
A Comparative Oncology Study of Iniparib Defines Its Pharmacokinetic Profile and Biological Activity in a Naturally-Occurring Canine Cancer Model
por: Saba, Corey, et al.
Publicado: (2016) -
Defining the Pharmacodynamic Profile and Therapeutic Index of NHS-IL12 Immunocytokine in Dogs with Malignant Melanoma
por: Paoloni, Melissa, et al.
Publicado: (2015) -
Pharmacokinetics and Pharmacodynamics of PARP Inhibitors in Oncology
por: Bruin, Maaike A. C., et al.
Publicado: (2022) -
Launching a Novel Preclinical Infrastructure: Comparative Oncology Trials Consortium Directed Therapeutic Targeting of TNFα to Cancer Vasculature
por: Paoloni, Melissa C., et al.
Publicado: (2009)